Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Journal of Neurosurgery.
Times cited: 145
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
Times cited: 362
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
New England Journal of Medicine.
Times cited: 1142